The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 beta (B.1.351) and other variants of concern in preclinical studies-Reference-Cited by-同舟云学术

The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 beta (B.1.351) and other variants of concern in preclinical studies

Published:2022-03 Issue: Volume:77 Page:103902
ISSN:2352-3964
Container-title:eBioMedicine
language:en
Short-container-title:eBioMedicine

Author:

Spencer Alexandra J^ORCID,Morris Susan,Ulaszewska Marta,Powers Claire,Kailath Reshma,Bissett Cameron,Truby Adam,Thakur Nazia,Newman Joseph,Allen Elizabeth R,Rudiansyah Indra,Liu Chang,Dejnirattisai Wanwisa,Mongkolsapaya Juthathip,Davies Hannah^ORCID,Donnellan Francesca R,Pulido David,Peacock Thomas P.,Barclay Wendy S.,Bright Helen,Ren Kuishu,Screaton Gavin,McTamney Patrick,Bailey Dalan,Gilbert Sarah C,Lambe Teresa

Publisher

Elsevier BV

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Reference48 articles.

1. Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study;Vasileiou;Lancet,2021

2. COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study;Hall;Lancet,2021

3. Covid-19: one dose of vaccine cuts risk of passing on infection by as much as 50%, research shows;Mahase;BMJ,2021

4. PHE. SARS-CoV-2 variants of concern and variants under investigation in England 2021 Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/988619/Variants_of_Concern_VOC_Technical_Briefing_12_England.pdf.

5. Effectiveness of BNT162b2 and mRNA-1273 Covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study;Chung;BMJ,2021

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Narrative Overview of Coronavirus Infection: Clinical Signs and Symptoms, Viral Entry and Replication, Treatment Modalities, and Management;Current Topics in Medicinal Chemistry;2024-08

2. Preclinical immune efficacy against SARS-CoV-2 beta B.1.351 variant by MVA-based vaccine candidates;Frontiers in Immunology;2023-12-12

3. Immunogenicity and safety of AZD2816, a beta (B.1.351) variant COVID-19 vaccine, and AZD1222 (ChAdOx1 nCoV-19) as third-dose boosters for previously vaccinated adults: a multicentre, randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study in the UK and Poland;The Lancet Microbe;2023-11

4. ChAdOx1 COVID vaccines express RBD open prefusion SARS-CoV-2 spikes on the cell surface;iScience;2023-10

5. Preclinical evaluation of a SARS-CoV-2 variant B.1.351-based candidate DNA vaccine;Vaccine;2023-10